Electrome
Private Company
Funding information not available
Overview
Electrome is positioning itself as a category leader in the emerging field of bioelectric medicine. Its core strategy involves an integrated platform combining a proprietary AI-powered discovery engine, a bioelectric data knowledge graph, and a modular hardware system to rapidly develop and commercialize non-invasive electroceuticals. With a first therapy for pain and inflammation prepared for launch via a 510(k) regulatory path, the company aims for near-term revenue while building a pipeline across high-burden diseases like wound healing, infectious disease, and oncology.
Technology Platform
Integrated platform comprising: 1) an AI Electroceutical Discovery Engine that maps and predicts optimal bioelectric signals; 2) a Bioelectric Data Knowledge Graph linking waveforms to biological responses; and 3) a Scalable, Modular Hardware Platform for manufacturing therapeutic devices.
Opportunities
Risk Factors
Competitive Landscape
Electrome competes in the emerging bioelectric medicine space with other neuromodulation and electroceutical startups, as well as established medical device firms (e.g., Boston Scientific, Abbott in neuromodulation for pain). Its differentiation lies in its integrated AI-driven discovery platform aimed at systematic signal identification and rapid pipeline generation.